Sarcoma Therapeutics Market by Type and Geography - Forecast and Analysis 2022-2026

The sarcoma therapeutics market share is expected to increase by USD 1.18 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 9%.

This sarcoma therapeutics market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers sarcoma therapeutics market segmentation by type (soft tissue sarcoma and osteosarcoma) and geography (North America, Europe, APAC, and Rest of the World (ROW)). The sarcoma therapeutics market report also offers information on several market vendors, including Adaptimmune Therapeutics plc, Advenchen Laboratories LLC, Agenus Inc., Agios Inc., Bayer AG, Bristol Myers Squibb Co., CytRx Corp., Eisai Co. Ltd., Epizyme Inc., GlaxoSmithKline Plc, Johnson and Johnson Inc., Karyopharm Therapeutics Inc., Mirati Therapeutics Inc., Novartis AG, PharmaMar SA, SillaJen Co. Ltd., Athenex Inc., Eli Lilly and Co., and Pfizer Inc. among others.

What will the Sarcoma Therapeutics Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Sarcoma Therapeutics Market Size for the Forecast Period and Other Important Statistics

 

Sarcoma Therapeutics Market: Key Drivers, Trends, and Challenges

The patient assistance programs is notably driving the sarcoma therapeutics market growth, although factors such as high treatment costs may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the sarcoma therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Sarcoma Therapeutics Market Driver 

One of the key factors driving the global sarcoma therapeutics market growth is the patient assistance programs due to the increasing cost of therapeutics for the treatment of various oncology indications. For instance, the US government has come up with initiatives such as the Patient Protection and Affordable Care Act, which is popularly known as Obamacare. It was passed in March 2010 and was implemented on January 1, 2014. So far, the law has resulted in the provision of health insurance coverage for about 94% of the US population. Furthermore, various pharmaceutical companies have come up with patient assistance programs to help patients. For instance, Novartis has initiated a patient assistance program for GLEEVEC called the GLEEVEC USD 10 Co-Pay card, which provides a month of supply of GLEEVEC for USD 10. These increasing initiatives to provide treatment at an affordable rate are expected to drive the growth of the market during the forecast period.

Key Sarcoma Therapeutics Market Trend

Another key factor driving the global sarcoma therapeutics market growth is the launch of various novel therapies. For instance, YONDELIS by Johnson & Johnson and LARTRUVO by Eli Lilly has shown high levels of efficacy and higher safety profiles for the treatment of sarcomas. YONDELIS is a DNA synthesis inhibitor and an alkylating agent, which responds quickly against tumor cells. The market is currently dominated by the sales of GLEEVEC for the treatment of sarcomas. As the patent expiry of GLEEVEC is nearing, the drug is expected to lose market share in the coming years. Other factors such as the approval of Ganitumab are expected to help in addressing the unmet needs in the market during the forecast period and further drive market growth in the forecast period.

Key Sarcoma Therapeutics Market Challenge

One of the key challenges to the global sarcoma therapeutics market growth is the high treatment costs. Vendors face a challenge in smaller specific markets primarily because of the limited distribution channels and the lack of awareness of know-how in local markets in these regions. Therefore, global players are entering into strategic alliances with small- and medium-sized pharmaceutical players that dominate the market in such regions to enhance the reach of drugs in local markets. Companies are also entering strategic alliances for the development of novel therapies in clinical phases for the transfer of technology, collaborative efforts to conduct studies in specific regions, and to ease the approval process at the regional level. However, the high cost is expected to limit the growth of the market in focus in the forecast period.

This sarcoma therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global sarcoma therapeutics market as a part of the pharmaceutical market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the sarcoma therapeutics market during the forecast period.

Who are the Major Sarcoma Therapeutics Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• Adaptimmune Therapeutics plc
• Advenchen Laboratories LLC
• Agenus Inc.
• Agios Inc.
• Bayer AG
• Bristol Myers Squibb Co.
• CytRx Corp.
• Eisai Co. Ltd.
• Epizyme Inc.
• GlaxoSmithKline Plc
• Johnson and Johnson Inc.
• Karyopharm Therapeutics Inc.
• Mirati Therapeutics Inc.
• Novartis AG
• PharmaMar SA
• SillaJen Co. Ltd.
• Athenex Inc.
• Eli Lilly and Co.
• Pfizer Inc.

 

This statistical study of the sarcoma therapeutics market encompasses successful business strategies deployed by the key vendors. The sarcoma therapeutics market is fragmented and the vendors are deploying growth strategies such as collaboration to compete in the market.

Product Insights and News

• adaptimmune.com - The company provides novel cell therapies to people with cancer.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The sarcoma therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Sarcoma Therapeutics Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the sarcoma therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Sarcoma Therapeutics Market?

For more insights on the market share of various regions Request for a FREE sample now!

37% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for sarcoma therapeutics in North America. Market growth in this region will be faster than the growth of the market in the Rest of the World (ROW).

The rapidly progressive nature and the severity of the indication are increasing the need for the development of novel drugs, which will facilitate the sarcoma therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The sarcoma therapeutics market in North America witnessed slightly low growth in 2020 due to the COVID-19 outbreak. The pandemic impacted many businesses and economies in the region. Supply chain disruptions in the pharmaceutical industry, owing to lockdown situations, hampered the market growth in 2020. However, the market is expected to return to normalcy, as a major portion of the US population has been completely vaccinated and the clinical trials of sarcoma therapeutics have resumed in the region.

What are the Revenue-generating Type Segments in the Sarcoma Therapeutics Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The sarcoma therapeutics market share growth by the soft tissue sarcoma segment will be significant during the forecast period. The launch of novel therapies in major markets will drive the growth of the market in focus through this segment in the coming years. For instance, GLEEVEC by Novartis accounted for approximately 25% of the market in 2020. 

This report provides an accurate prediction of the contribution of all the segments to the growth of the sarcoma therapeutics market size and actionable market insights on post COVID-19 impact on each segment.

You may be interested in:

Kaposi Sarcoma market - The market size has the potential to grow by USD 20.89 million during 2021-2025, and the market's growth momentum will accelerate at a CAGR of 3.10%. 

Ewings Sarcoma Treatment market - The market share is expected to increase by USD 302.5 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.9%.

Sarcoma Therapeutics Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 9%
Market growth 2022-2026	$ 1.18 billion
Market structure	Fragmented
YoY growth (%)	7.8
Regional analysis	North America, Europe, APAC, and Rest of World (ROW)
Performing market contribution	North America at 37%
Key consumer countries	US, Canada, China, Germany, and UK
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	Adaptimmune Therapeutics plc, Advenchen Laboratories LLC, Agenus Inc., Agios Inc., Bayer AG, Bristol Myers Squibb Co., CytRx Corp., Eisai Co. Ltd., Epizyme Inc., GlaxoSmithKline Plc, Johnson and Johnson Inc., Karyopharm Therapeutics Inc., Mirati Therapeutics Inc., Novartis AG, PharmaMar SA, SillaJen Co. Ltd., Athenex Inc., Eli Lilly and Co., and Pfizer Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Sarcoma Therapeutics Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive sarcoma therapeutics market growth during the next five years
• Precise estimation of the sarcoma therapeutics market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the sarcoma therapeutics industry across North America, Europe, APAC, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of sarcoma therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch